All News

Open to all health care professionals, the PQA meeting is a top forum for learning best practices and emerging trends in medication services, pharmacist-provided care and quality improvement initiatives.

Study suggests a link between vitamin D deficiency and COVID-19 severity and mortality.

It is critical for pharmacists to inquire about the use of e-cigarette or vaping products in patients that present with certain symptoms.

Results of an excess-deaths analysis show that 18.2 million individuals have likely died as a result of the pandemic.

Medication therapy management programs enhance communication, spur innovation.

Sandostatin treats severe diarrhea and flushing associated with metastatic carcinoid tumors, as well as treatment of acromegaly.

Acid controllers relieve heartburn associated with indigestion.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the understanding of malignant lymphomas’ pathobiology and relationship with the immune system evolved during her clinical and investigational research into the subject.

Previous research has shown that genetic factors contribute immensely to the risk of migraine.

This month's featured products include treatments for insomnia, atopic dermatitis, and more.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the field of hematopathology has changed over the last decade.

Professional assistance programs provide pathway for health care professionals to return to practice following treatment for substance use disorder.

Pharmacy Times will be covering the upcoming Hematology and Oncology Pharmacy Association (HOPA) Association Annual Conference live in Boston, Massachusetts, taking place March 30 through April 2.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A chainmail-like, flexible outer layer on Clostridium difficile may explain its success at defending itself against antibiotics.

Simulations of disease spread show that wearing masks for at least 2 weeks after achieving goal of a minimum of 70% population coverage saves money and reduces deaths and hospitalizations.

Asmanex HFA is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses her American Society for Investigative Pathology Gold-Headed Cane Award lecture at the Experimental Biology 2022 conference on the classification of lymphoma in the modern era.

Pharmacists are an important part of the care team for patients with bleeding disorders, providing services such as medication counseling and reconciliation.

As the profession moves more toward the internet, it is helpful to know how to best use the various platforms.

Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.

Jeffrey B. Simon, JD, co-chair of the National Opioid Litigation Conference, discusses some steps that pharmacists could take to help address the opioid epidemic in the pharmacy.

Ideally, these contracts help address criticism of the 340B program, improve patient outcomes, and increase compliance.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the endpoints of the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.